Chafe, Shawn C;
Zhai, Kui;
Aghaei, Nikoo;
Miletic, Petar;
Huang, Zhi;
Brown, Kevin R;
Mobilio, Daniel;
... Singh, Sheila K; + view all
(2025)
A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis.
Science Translational Medicine
, 17
(805)
10.1126/scitranslmed.adu2459.
Preview |
Text
BACE1manuscript.pdf - Accepted Version Download (20MB) | Preview |
Abstract
Brain metastasis occurs in up to 40% of patients with non–small cell lung cancer (NSCLC). Considerable genomic heterogeneity exists between the primary lung tumor and respective brain metastasis; however, the identity of the genes capable of driving brain metastasis is incompletely understood. Here, we carried out an in vivo genome-wide CRISPR activation screen to identify molecular drivers of brain metastasis from an orthotopic xenograft model derived from a patient with NSCLC. We found that activating expression of the Alzheimer’s disease–associated beta-secretase 1 (BACE1) led to a substantial increase in brain metastases. Furthermore, genetic and pharmacological inhibition of BACE1 blocked NSCLC brain metastasis. Mechanistically, we identified that BACE1 acts through epidermal growth factor receptor to drive this metastatic phenotype. Together, our data highlight the power of in vivo CRISPR activation screening to unveil molecular drivers and potential therapeutic targets of NSCLC brain metastasis.
Archive Staff Only
 |
View Item |
